行情

ALKS

ALKS

阿尔凯默斯
NASDAQ

实时行情|Nasdaq Last Sale

18.99
-0.04
-0.21%
交易中 13:25 07/16 EDT
开盘
18.92
昨收
19.03
最高
19.07
最低
18.48
成交量
69.84万
成交额
--
52周最高
25.35
52周最低
11.98
市值
30.14亿
市盈率(TTM)
-21.5233
分时
5日
1月
3月
1年
5年

分析师评级

13位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ALKS价格均价为19.09,最高价位26.00,最低价为16.00。

EPS

ALKS 新闻

更多
Did Hedge Funds Make The Right Call On Alkermes Plc (ALKS) ?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds
Insider Monkey · 3天前
Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?
Zacks · 06/30 14:36
Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program
PR Newswire · 06/29 12:00
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
Alkermes plc (Nasdaq: ALKS) today announced that 10 nonprofit organizations have been awarded grants from the company's COVID-19 Relief Fund, a special edition of the company's signature Alkermes Inspiration Grants® program, that was established to assist nonp
PR Newswire · 06/24 11:00
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
PR Newswire · 06/22 14:01
Alkermes Highlights New Preclinical Data On ALKS 4230 In Combo With Lucitanib Presented At AACR
 Alkermes plc (NASDAQ:ALKS) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of ALKS 4230, Alkermes'
Benzinga · 06/22 13:19
Alzheimer's Drug Approval More Critical for Biogen After Patent Decision
GuruFocus.com · 06/19 23:04
Edited Transcript of ALKS earnings conference call or presentation 29-Apr-20 12:00pm GMT
Thomson Reuters StreetEvents · 06/16 12:28

所属板块

生物技术和医学研究
-0.91%
制药与医学研究
-0.81%

热门股票

代码
价格
涨跌幅

ALKS 简况

Alkermes Public Limited Company是一家生物制药公司。该公司与合作伙伴或自己独立研究、开发和商业化旨在解决治疗领域患者医疗需求的药品。该公司拥有约20种产品和一系列针对中枢神经系统(CNS)疾病(如精神分裂症、抑郁症、成瘾和多发性硬化)的临床候选产品。该公司的产品包括ARISTADA、VIVITROL、RISPERDAL CONSTA、INVEGA SUSTENNA/XEPLION与INVEGA TRINZA、AMPYRA/FAMPYRA、BYDUREON、ALKS 5461、ALKS 3831、ALKS 8700、ALKS 6428、Aripiprazole Lauroxil两月剂量、ALKS 7119和RDB 1450。该公司产品平台包括可注射缓释微球技术、LinkeRx技术、纳米晶体技术和口服控释技术。
展开

微牛提供Alkermes Plc(NASDAQ-ALKS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ALKS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ALKS股票基本功能。